Low incidence of clinical actionable alterations in the RTK/RAS/RAF and PI3K/AKT/mTOR pathways indicated that the subtype might not be beneficial to the conventional targeted therapy of NSCLC. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.